Rigel Pharma (NASDAQ: RIGL) reported Q3 EPS of ($0.14), $0.01 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $3.93 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.